Setmelanotide
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Rhythm · Phase 2 · Completed · Enrollment 40
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Setmelanotide 0.5 mg | 0 participants | n/r | n/r | n/r | 0 |
| Setmelanotide 1.5 mg | 0 participants | n/r | n/r | n/r | 0 |
| Setmelanotide 2.5 mg | 0 participants | n/r | n/r | n/r | 0 |
| Placebo | 1 participants | n/r | n/r | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.